Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014-02-20
Reducing local therapy in patients responding to preoperative systemic therapy: are we outsmarting ourselves?
Related Questions
New answer by Radiation Oncologist at Varian Medical Systems/Allegheny health network (September 11, 2023)
This is part of ongoing/completed B51 and practices have a wide variation.
In our practice, if it is t1 or t2 primary with non triple negative phenotype breast cancer and pCR...
The tumor was initially 5.5 cm in size.
Mastectomy and ALND revealed a grade 2, ER/PR positive HER-2 negative tumor with negative surgical marg...
New comment by Radiation Oncologist at Northeast Alabama Regional Medical Center ( March 25, 2022)
Thank you, @Lawrence B. Marks, for the thought process and logic.
In a woman with high-grade, clinically node positive invasive ductal carcinoma who receives neoadjuvant chemotherapy and breast conserving surgery, wo...
New comment by Radiation Oncologist at UNC School of Medicine ( January 17, 2023)
@Abe: Masterful summary as always. I always learn something new (or relearn something old that I have forgotten). Nevertheless, I would caution us making decisions based only ...
The patient had 0/2 sentinel lymph nodes involved, and mastectomy revealed pT3 disease with negative margins
New answer by Radiation Oncologist at Memorialcare Saddleback Medical Center (July 7, 2023)
Short answer: Yes. Progression through chemotherapy is a poor prognostic indicator and therefore, PMRT + RNI should be given. Long answer: T3N0 represents a spectru...